MSD Animal Health Unveils Next-Generation FALCON® at Aqua Nor 2023

Aqua Nor, Trondheim — 19th-21st August: MSD Animal Health, a subsidiary of Merck & Co., Inc., has officially launched its advanced FALCON® vision technology aimed at revolutionizing fish farming practices. This innovative system is designed to enhance fish health and biomass production through effective welfare monitoring and early detection of sea lice.

Revolutionizing Aquaculture through Technology

The new generation FALCON system combines state-of-the-art vision technology with artificial intelligence, delivering near real-time insights into sea lice prevalence and the overall health condition of fish populations. This technological advancement promises to optimize fish welfare and boost biomass production across aquaculture facilities.

Key Features of the FALCON System

• High-Resolution Imaging: Utilizing advanced stereovision and high-resolution cameras, FALCON captures thousands of images daily for comprehensive biomass estimation and fish monitoring.
• AI-Driven Analytics: The system employs a neural network to automatically detect sea lice and assess fish welfare, significantly minimizing the need for manual sampling and reducing stress on fish.
• Cloud-Based Dashboard: Users can access real-time insights securely stored in the cloud, offering critical updates on fish growth and overall health metrics from any location.
• Optimized Decision-Making: Near real-time data empowers aquaculture operators to make informed decisions regarding lice management and treatment protocols, enhancing productivity while promoting sustainability.

Significance of the New Generation FALCON

According to Dafydd Morris, General Manager of MSD Animal Health Aqua EURAM, “The launch of this system is a crucial advancement in sustainable aquaculture. It enables earlier detection of fish lice, which is essential for effective treatment and health management.” The system also provides critical data for assessing treatment effectiveness, promoting continuous improvement in fish welfare.

Upcoming Research and Events at Aqua Nor

In addition to the FALCON launch, MSD Animal Health will present new research regarding a sensitivity test for salmon lice larvae (Lepeophtheirus salmonis) aimed at enhancing the sustainable use of sea lice medications. This presentation is scheduled for 2 PM on Wednesday, 20th August.

Integrating Biopharmaceuticals with Technology

Morris elaborates, “FALCON complements our broad portfolio, which includes the CLYNAV® vaccine — a DNA-based solution for protecting Atlantic salmon against pancreas disease. Our integration of pharmaceuticals and technology underscores our commitment to enhancing aquaculture sustainability.”

Engagement and Learning Opportunities

MSD Animal Health will also host two “Lunch and Learn” sessions at Aqua Nor, focusing on enhancing fish welfare through technology and biopharmaceuticals. The first session on vision technology is set for 1 PM on Wednesday, 20th August, while the second, discussing topics like lice prevention and handling practices, will take place at the same time on Thursday, 21st August.

Conclusion

With the rollout of the FALCON system in Norway, planned market expansion is slated for 2026. For more details about the FALCON technology, visit www.aquafalcon.com.

*CLYNAV® is a prescription-only veterinary medicine. Use only under veterinary supervision and in accordance with local regulations.